54 results about "Sialoglycoprotein" patented technology

Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglyco-protein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA)-glutamate (GIu) and may comprise the amino acid sequence serine (Ser)-Alanine (Ala)-amino-naphthoic acid (ANA)-glutamate (GIu). In such cases, the enzyme of interest is typically CPG2.

The invention provides a method for isolating and identifying disseminated liver cancer cells. The method is based on a de-ASGPR on a liver cancer cell membrane and in the method, a ligand or antibody of the de-ASGPR is combined with a liver cancer cell, a bead is used to mark the liver cancer cell indirectly for positive isolation and enrichment, a immunocytochemistry method or a flow cytometry is adopted to identify and inspect to judge whether any liver cancer cells exist in the sample. The method can be used for the diagnosis, metastasis, recurrent forecasting and efficacy monitoring of liver cancer, can be used to detect disseminated liver cancer cells and is high in sensibility, good in specificity and convenient to operate.

The invention provides a paramagnetic metal complex and a synthetic method and application thereof. The paramagnetic metal complex is an arabinogalactan-modified 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacethyl paramagnetic metal complex. A magnetic resonance imaging contrast agent prepared from the paramagnetic metal complex has high stability, water solubility and relaxation rate and is targeted to liver and kidney, so that targeted imaging is realized, and the imaging contrast and definition are improved. The paramagnetic metal complex has a good effect on raising the early diagnosis levels of diseases of liver and kidney organs, is about 2 times the relaxation rate of dotarem, has very long targeted radiography imaging time, can be easily prepared into a solution with required concentration for intravenous injection, is suitable for sterilizing and disinfecting with a hot pressing method, can be selectively identified by an asialoglycoprotein receptor on a liver parenchyma surface, and has high selectivity on livers of human beings or other mammals.

An isolated and purified glycoprotein and functional analogues thereof are disclosed. The glycoproteins are characterized by being expressed on at least primitive hematopoietic cells, and being a ligand for L-selectin. The binding activity of the ligand of the present invention to L-selectin is not sulfation-dependent and it is neither inhibited by anti-CD34 antibodies nor by MECA-79 monoclonal antibody and the ligand is resistant to O-sialoglycoprotein endopeptidase activity. Further, the present invention provides a method of performing an overlay adherence assay by using isolated cells or cell lines as a substrate. The cells are prepared as the substrate for the assay using a cytocentrifuge with a modified sample chamber allowing placement of the cytocentrifuged cell pellet to any selected location on the slide as required by the shear conditions employed for any given assay.

The invention discloses a liver targeting taxol nanometer suspension and a preparation method of the liver targeting taxol nanometer suspension. Taxol serves as therapeutic, poloxamer F127 modified by lactobionic acid serves as a stabilizer, the liver targeting taxol nanometer suspension is prepared with an ultrasonic coprecipitation united high pressure homogenizing method, the particle size ranges from 160 nm to 200 nm, and the polydispersity index is 0.2 +/- 0.012. According to the nanometer suspension, the galactose residue on the poloxamer F127 is acylated by lactobionic acid, asialoglycoprotein receptors on liver surface parenchyma cells are recognized, and the effect of liver targeted drug delivery is achieved.

New methods for diagnosing, treating, and monitoring cancer have been developed based on the expression level of markers, such as transcobalamin II (TCII), transcobalamin II receptor (TCIIR), Ki-67, megalin, cubilin, amnionless and/or asialoglycoprotein receptors. For example, a cancer diagnosis can be made by determining the level of TCII, TCIIR, Ki-67, megalin, cubilin, amnionless and/or asialoglycoprotein receptor expression in a test sample from the subject and in a reference sample, and diagnosing the subject as having cancer if the level of expression of transcobalamin II (TCII), transcobalamin II receptor (TCIIR), Ki-67, megalin, cubilin, amnionless, an asialoglycoprotein receptor, or a combination thereof, is statistically significantly different than the respective reference sample.

The invention relates to a polyethylene glycol-lactobionic acid modified aminated hectorite nano particle as well as a preparation method and application thereof. The preparation method of the polyethylene glycol-lactobionic acid modified aminated hectorite nano particle comprises the following steps: firstly, carrying out reaction on lactobionic acid with polyethylene glycol, wherein one end of the polyethylene glycol is an amino group, and the other end of the polyethylene glycol is a carboxyl, so that pegylated lactobionic acid is obtained; secondly, modifying hectorite with (3-aminopropyl) dimethyl ethoxy silane, so that a certain amount of amino groups are formed on the surface of the hectorite; thirdly, modifying nano clay hectorite with the pegylated lactobionic acid, so that a lactobionic acid modified functional hectorite nano composite material is obtained; the lactobionic acid modified functional hectorite nano composite material can be used for preparing a nano medicine carrying system with a lactobionic acid targeting function. The polyethylene glycol-lactobionic acid modified aminated hectorite nano particle has the advantages that stability and biological compatibility of a nano particle are improved, and a specific targeting effect on liver cancer cells highly expressed by an asialoglycoprotein receptor is realized, so that a synthesized nano medicine carrying composite material can be applied to targeted delivery of an anti-cancer drug. The preparation method of the polyethylene glycol-lactobionic acid modified aminated hectorite nano particle is simple, mild in reaction conditions and easy to operate and has an industrialization implementation prospect.

Methods and kits for detecting hepatocellular carcinoma recurrence or metastasis, and of measuring markers of hepatocellular carcinoma, including markers of hepatocellular carcinoma recurrence or metastasis, in a blood sample obtained from a subject by (a) isolating circulating tumor cells (CTCs) by contacting a blood sample obtained from the subject with a set of capture antibodies, wherein the capture antibodies specifically bind asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM); (b) contacting the isolated CTCs with an antibody that specifically binds vimentin; and (c) measuring the number of vimentin-positive CTC.

The invention relates to a double targeting hepatic tumor drug as well as a synthetic method and application thereof. The double targeting hepatic tumor drug has a terminal structure (galactose or N-acetyl galactose) capable of specifically binding to asialoglycoprotein receptor at the surface of a hepatocyte, and therefore the double targeting hepatic tumor drug is capable of binding to the asialoglycoprotein receptor so as to be brought into the interior of a hepatic tumor cell by means of the endocytosis of the hepatic tumor cell. On the other hand, experiments prove that the enzyme hydrolysis of the overexpressed cathepsin B in hepatic tumor cell lysosome is performed on the double targeting hepatic tumor drug to release Adriamycin, that is, active ingredients are released while the level of cathepsin B can be reduced, so as to slow down tumor progression. In summary, the double targeting hepatic tumor drug prepared by the invention uses asialoglycoprotein receptor and cathepsin Bas double target spots for having an effect, has obvious therapeutic effect, and meanwhile significantly reduces the toxic and side effects on other normal tissues and cells.

The invention discloses a hepatoma targeting carbon nano tube loaded with doxorubicin hydrochloride and a preparation method thereof. Amidation reaction of amino in a chitosan structure and carboxyl in lactobionic acid is carried out; galactosyl is coupled to chitosan so as to obtain galactosylated chitosan; the galactosylated chitosan is modified onto the carbon nano tube; therefore, the water solubility and the biocompatibility of the carbon nano tube are increased; simultaneously, the specificity of non-reductive galactose or N-acetyl-galactose is identified and taken by utilizing an asialoglycoprotein acceptor on a liver parenchyma cell membrane, so that the active hepatoma targeting effect is realized; simultaneously, doxorubicin hydrochloride is combined with a vector in a non-covalent manner through phi-phi accumulation acting force; and therefore, the hepatoma targeting carbon nano tube loaded with doxorubicin hydrochloride is prepared. The hepatoma targeting carbon nano tube disclosed by the invention is simple in preparation process, moderate in experimental condition and easy to operate; release of the medicine loaded targeting carbon nano tube has pH dependency, good biocompatibility and obvious in-vivo tumour inhibition effect; and thus, the hepatoma targeting carbon nano tube has good practical value.

The invention relates to a chitosan modification method which solves the problems that a traditional modification method is complex in operation and mainly depends on the size and surface property of particles, and obtained chitosan is poor in specific recognition and can not be recognized by asialoglycoprotein in liver parenchymal cells in a targeting mode. The chitosan modification method comprises the steps that chitosan is dissolved in a diluted hydrochloric acid solution, so that acidulated chitosan is obtained; lactobionic acid is dissolved in water, so that a lactobionic acid solution is obtained; N, N'-dicyclohexyl carbodiimide is dissolved in tetramethylethylenediamine, so that activated N, N'-dicyclohexyl carbodiimide is obtained; the lactobionic acid solution and the activated N, N'-dicyclohexyl carbodiimide are dripped into the acidulated chitosan, a mixture is obtained, filtered, dialyzed through a dialysis bag and dried in a vacuum mode, and the modified chitosan is obtained.

The present application discloses a preparation for inhibiting candida albicans. The active ingredient of the preparation contains an SAalpha2-3Gal sugar chain structure (especially glycoproteins richin SAalpha2-3Gal sugar chain structure), and with the increase of a sialic acid glycoprotein concentration, the inhibitory effect on candida albicans growth is significantly enhanced; when the concentration of sialic acid protein is in the range of 100-200 [mu]g/mL, the preparation has a significant inhibitory effect on adhesion of CAL-27 cells by the candida albicans, and when the concentrationof the sialic acid glycoprotein reaches 200 [mu]g/mL, the candida albicans hardly grows, the preparation can play a sterilizing role; and the preparation can be sprayed directly on potential parts such as skin surfaces and oral cavities where the candida albicans grows, the active ingredient of the preparation is preferably a glycoprotein rich in SAalpha2-3Gal sugar chain structure separated and purified from milk.

The present invention provides an engineered regulatory T cell (Treg) comprising a chimeric antigen receptor (CAR) wherein the CAR comprises an antigen recognition domain that specifically binds to an asialoglycoprotein receptor (ASGR). The present invention also provides a method of promoting liver tissue repair and/or regeneration in a subject comprising the step of administering to the subject an engineered Treg comprising a CAR or a pharmaceutical composition comprising the engineered Treg wherein the CAR comprises a liver-specific antigen recognition domain.

The invention relates to the technical field of enzyme-linked immunosorbent assay reagents, and discloses an enzyme-labeled antibody protection liquid, which comprises the following components: sialoglycoprotein (derived from cubilose), gelatin (derived from cattle), Procline 200, Triton X-100 and polyvinylpyrrolidone, wherein the pH value is adjusted to 7.4 by using a 0.1 M phosphate buffer. According to the enzyme-labeled antibody protection liquid, sialoglycoprotein from cubilose is adopted as protection protein, is protein with good water-retaining property, has a good protection effect on antibodies and enzymes, is from saliva of canaries and does not contain immune globulin, so that the problem that an existing enzyme-labeled antibody protection liquid cannot be suitable for enzyme-linked immunosorbent assay containing immune globulin or enzyme-linked immunosorbent assay with the immune globulin as a detection object due to the fact that the existing enzyme-labeled antibody protection liquid contains the immune globulin is solved.

The invention discloses a tissue-targeted protein targeted-degradation compound and application thereof, relates to the field of pharmacy, and particularly relates to a compound or pharmaceutically acceptable salt, stereoisomer, solvate or polymorphic substance thereof. The compound is a protein targeted-degradation chimera with tissue targeting ability. A structure of the compound comprises three parts: A-BD-CON, wherein the part A is a protein targeted-degradation chimera (PROTAC), one end of the structure of the part A is a target protein binding ligand, and the other end of the structure of the part A is a ubiquitin ligase ligand; and the part CON is a ligand of an asialoglycoprotein receptor (ASGPR) and has a function of targeting a specific tissue of the PROTAC. On the basis of the protein targeted-degradation chimera (PROTAC) which is very difficult in medicine preparation, the functions of liver tissue enriching and cell targeting are further realized, and the solubility, the cell permeability and the drug effect in specific target tissues of the PROTAC are improved, so that the medicine preparation property of the PROTAC is improved on the whole.